急性心衰出院后快速优化指南导向药物治疗的剂量与结局关系:STRONG-HF 二次分析
该研究为 STRONG-HF 随机临床试验的二次分析,纳入 515 例接受高强度治疗的高危急性心衰患者,评估出院后 2 周内达到的指南导向药物治疗(GDMT)剂量与 180 天心衰再入院或死亡及 90 天生活质量的关系。结果显示,平均优化剂量每增加 10%,180 天主要终点风险降低(aHR 0.89),全因死亡风险降低(aHR 0.84),高剂量组不良事件更少。
要点
- 出院后 2 周内多数患者可达到中高剂量 GDMT,且安全性良好。
- GDMT 平均优化剂量每提高 10%,180 天心衰再入院或全因死亡风险降低 11%。
- 血压较低和淤血较重的患者更难以在 2 周内上调至目标剂量。
核心结论
- 在高强度治疗组中,出院后 2 周达到较高 GDMT 剂量可行且安全,并与更好的 180 天结局相关。
研究设计与样本
- STRONG-HF 随机临床试验的事后二次分析,纳入 515 例急性心衰入院后未使用最佳剂量 GDMT 的患者。
- 计算肾素-血管紧张素系统抑制剂、β受体阻滞剂和盐皮质激素受体拮抗剂三类药物平均剂量占目标剂量的百分比,分为低(<50%)、中(≥50%至<90%)、高(≥90%)三组。
- 采用 Cox 回归模型将剂量作为时间依赖协变量分析。
主要发现
- 2 周时低剂量组 39 例(7.6%),中剂量组 254 例(49.3%),高剂量组 222 例(43.1%)。
- 至 90 天,较高 GDMT 剂量组不良事件发生频率更低。
临床怎么用
- 对急性心衰出院患者,可考虑在密切监测下于 2 周内快速上调 GDMT 至目标剂量。
- 血压较低和淤血较重的患者需更谨慎评估上调剂量可行性。
局限性
- 为事后二次分析,结果需谨慎解读。
- 仅纳入高强度治疗组患者,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The Safety, Tolerability, and Efficacy of Rapid Optimization, Helped by N-Terminal Pro-Brain Natriuretic Peptide Testing of Heart Failure Therapies (STRONG-HF) trial strived for rapid uptitration aiming to reach 100% optimal doses of guideline-directed medical therapy (GDMT) within 2 weeks after discharge from an acute heart failure (AHF) admission. OBJECTIVE: To assess the association between degree of GDMT doses achieved in high-intensity care and outcomes. DESIGN, SETTING, AND PARTICIPANTS: This was a post hoc secondary analysis of the STRONG-HF randomized clinical trial, conducted from May 2018 to September 2022. Included in the study were patients with AHF who were not treated with optimal doses of GDMT before and after discharge from an AHF admission. Data were analyzed from January to October 2023. INTERVENTIONS: The mean percentage of the doses of 3 classes of HF medications (renin-angiotensin system inhibitors, β-blockers, and mineralocorticoid receptor antagonists) relative to their optimal doses was computed. Patients were classified into 3 dose categories: low (<50%), medium (≥50% to <90%), and high (≥90%). Dose and dose group were included as a time-dependent covariate in Cox regression models, which were used to test whether outcomes differed by dose. MAIN OUTCOME MEASURES: Post hoc secondary analyses of postdischarge 180-day HF readmission or death and 90-day change in quality of life. RESULTS: A total of 515 patients (mean [SD] age, 62.7 [13.4] years; 311 male [60.4%]) assigned high-intensity care were included in this analysis. At 2 weeks, 39 patients (7.6%) achieved low doses, 254 patients (49.3%) achieved medium doses, and 222 patients (43.1%) achieved high doses. Patients with lower blood pressure and more congestion were less likely to be uptitrated to optimal GDMT doses at week 2. As a continuous time-dependent covariate, an increase of 10% in the average percentage optimal dose was associated with a reduction in 180-day HF readmission or all-cause death (primary end point: adjusted hazard ratio [aHR], 0.89; 95% CI, 0.81-0.98; P = .01) and a decrease in 180-day all-cause mortality (aHR, 0.84; 95% CI, 0.73-0.95; P = .007). Quality of life at 90 days, measured by the EQ-5D visual analog scale, improved more in patients treated with higher doses of GDMT (mean difference, 0.10; 95% CI, -4.88 to 5.07 and 3.13; 95% CI, -1.98 to 8.24 points in the medium- and high-dose groups relative to the low-dose group, respectively; P = .07). Adverse events to day 90 occurred less frequently in participants with HIC who were prescribed higher GDMT doses at week 2. CONCLUSIONS AND RELEVANCE: Results of this post hoc analysis of the STRONG-HF randomized clinical trial show that, among patients randomly assigned to high-intensity care, achieving higher doses of HF GDMT 2 weeks after discharge was feasible and safe in most patients. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03412201.
引用
- Cotter, Deniau, Davison, et al. Optimization of Evidence-Based Heart Failure Medications After an Acute Heart Failure Admission: A Secondary Analysis of the STRONG-HF Randomized Clinical Trial. JAMA Cardiol. 2024. PMID: 38150260. doi:10.1001/jamacardio.2023.4553
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。